Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | ICMT | O60725 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13129949 | 1.00 | FFAR1 (0.46) | FFAR1ICMTMMP12NAAACNR2 | |
| SCHEMBL14596301 | 0.87 | ICMT (0.46) | FFAR1ICMTMMP12NAAAFFAR4 | |
| SCHEMBL13883693 | 0.85 | ICMT (0.51) | FFAR1ICMTMMP12NAAAFFAR4 | |
| SCHEMBL2813151 | 0.80 | FFAR1 (0.53) | FFAR1MMP12NAAACNR2FFAR4 | |
| SCHEMBL13129947 | 0.77 | ICMT (0.47) | FFAR1ICMTMMP12NAAAFFAR4 | |
| SCHEMBL4593507 | 0.76 | ICMT (0.51) | FFAR1ICMTMMP12FFAR4TRPV1 | |
| SCHEMBL9637227 | 0.74 | FFAR1 (0.48) | FFAR1MMP12MMP13TRPV1KCNH2 | |
| SCHEMBL14596300 | 0.73 | ICMT (0.72) | ICMTALDH1A1 | |
| SCHEMBL5445097 | 0.73 | ICMT (0.72) | ICMTALDH1A1 | |
| SCHEMBL5808516 | 0.71 | FFAR1 (0.58) | FFAR1MMP12NAAACNR2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324378-B2 | Prodrugs and conjugates of prenylation inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | FNTA, FNTB, FDPS | FFAR1 2841/4885ICMT 458/4885MMP12 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.